{"id":"NCT01552057","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Duloxetine in Fibromyalgia","officialTitle":"A Phase III Clinical Trial of Duloxetine in Participants With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2012-03-13","resultsPosted":"2014-12-19","lastUpdate":"2015-01-16"},"enrollment":393,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"Duloxetine 60 mg","otherNames":["LY248686","Cymbalta"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Duloxetine 60 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to assess the effectiveness and safety of duloxetine in participants with fibromyalgia.","primaryOutcome":{"measure":"Change From Baseline to 14-Week Endpoint in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (MMRM)","timeFrame":"Baseline, 14 weeks","effectByArm":[{"arm":"Duloxetine 60 mg","deltaMin":-1.9,"sd":0.23},{"arm":"Placebo","deltaMin":-1.58,"sd":0.23}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0988"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":20},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["26296539"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":194},"commonTop":["Somnolence","Nasopharyngitis","Nausea","Constipation","Thirst"]}}